Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468894 | 0.87 | ALDH1A1 (0.52) | KDM4EALDH1A1HTR5ASMN1; SMN2 | |
| SCHEMBL25176236 | 0.83 | ALDH1A1 (0.42) | KDM4EALDH1A1HTR5ASMN1; SMN2 | |
| SCHEMBL5467950 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1HTR5APIM1 | |
| SCHEMBL15499270 | 0.79 | KDM4E (0.36) | KDM4EALDH1A1HTR5APIM1 | |
| SCHEMBL5467975 | 0.78 | KDM4E (0.35) | KDM4EALDH1A1HTR5APIM1 | |
| SCHEMBL16254658 | 0.77 | — | — | |
| SCHEMBL5474905 | 0.75 | ALDH1A1 (0.48) | KDM4EALDH1A1HTR5ASMN1; SMN2 | |
| SCHEMBL18226053 | 0.74 | KDM4E (0.38) | KDM4EALDH1A1HTR5A | |
| SCHEMBL24456723 | 0.74 | ALDH1A1 (0.38) | KDM4EALDH1A1HTR5ASMN1; SMN2 | |
| SCHEMBL15262863 | 0.74 | KDM4E (0.38) | KDM4EALDH1A1HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| WO-2017141927-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | 大正製薬株式会社 | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | KDM4E 134/4885ALDH1A1 254/4885HTR5A 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.